The journal Clinical Ophthalmology publishes a new article by Dr. Monés and his scientific team, Dr. Badal and Marc Biarnés, entitled “Bimonthly half-dose ranibizumab in large pigment epithelial detachment and retinal angiomatous proliferation with high risk of retinal pigment epithelium tear: a case report”.
The study proposes an innovative approach in the treatment of retinal angiomatous proliferation. This pathology, a subtype of age-related macular degeneration (AMD), leads to serious damage with a high risk of retinal pigment epithelial detachments during treatment of the disease. In cases where tearing of the epithelium occurs, the patient suffers irreversible loss of visual acuity.
In the article, which was published in the June edition of Clinical Ophthalmology, the researchers propose a bimonthly treatment with a half dose of the intravitreal injections used to cure other AMD subtypes. In this way, the final dose applied to the patient is the same as in other protocols but the risk of tearing the pigment epithelium is minimised, providing the best guarantees for maintaining the patient’s visual acuity.
Dr. Mones believes that “this work demonstrates how far we have to go in the field of eye disease and how much scientific research can contribute. Despite the latest progress, we must remain committed to patients and continue to invest our efforts and resources so we can discover new treatments which improve quality of life.”
For the original article published by Clinical Ophthalmology click here.